Posts by Follicle Thought
Eirion Therapeutics Initiates Phase 1 Trial for ET-02 in Androgenic Alopecia
There is more news in the androgenic alopecia space, as Eirion Therapeutics begins a Phase 1 trial for ET-02, a topical treatment. What is ET-02? According to Eirion Therapeutics, ET-02 works by targeting hair follicle stem cells that have become defective or inactive in individuals suffering from androgenic alopecia, enabling hair follicles to resume normal…
Read MoreTOP-M119: Topadur Pharma and Oshen Holdings To Develop New Androgenic Alopecia Treatment
Correction (07/05/2024): Topadur Pharma has been in contact (read the comments below) and let us know that TOP-M119 does not contain sildenafil and nitroglycerin. We have corrected the reference to this in the article below. The information originated from a website called Il Messaggero, quote “The most curious thing is that the currently candidate drug,…
Read MoreEQ101 Demonstrates Efficacy and Tolerability for Alopecia Areata Treatment
Equillium, a clinical-stage biotechnology company, has reported its findings from a phase 2 study of EQ101, a new treatment for patients with moderate to severe alopecia areata (AA). What is EQ101? EQ101 is a first-in-class, selective, tri-specific inhibitor that targets IL-2, IL-9, and IL-15 proteins involved in the immune response. These proteins have been implicated…
Read MoreLumenis Launches Folix: An FDA-Cleared Fractional Laser For Hair Loss
Lumenis Be. Ltd, an energy-based medical device company specializing in aesthetic and eye care solutions, has introduced FoLix™, a fractional laser system for treating hair loss. Recently cleared by the FDA, FoLix is the first fractional laser to be cleared for hair loss treatment for both women and men in the United States. What is…
Read MoreSoterios Pharma Announces Phase 2 Results for Alopecia Areata Treatment STS-01
Soterios Pharma, a biopharmaceutical company based in the UK, has announced promising topline results from their Phase 2 study of STS-01, a topical treatment for mild-to-moderate alopecia areata (AA). What is STS-01? STS-01 is a topical treatment for alopecia areata. It is a cytokine-targeting agent that modulates the inflammatory response and T-cell proliferation by disrupting…
Read MoreJW Pharmaceutical Unveils Results From its Mouse Study of JW0061
JW Pharmaceutical has presented positive preclinical data on JW0061, a novel Wnt-targeted hair loss treatment, at the U.S. Society of Investigative Dermatology meeting. What are Wnt-Targeted Hair Loss Treatments? Wnt-targeted hair loss treatments aim to modulate the Wnt/ß-catenin signaling pathway, which plays an important role in hair follicle development, hair growth cycle regulation, and hair…
Read MoreKintor Releases Phase 2 Trial Results for GT20029
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Read MoreInterview with CEO of Stemson Therapeutics, Geoff Hamilton – Updates and the Future
Follicle Thought is pleased to present a recent interview we conducted with Geoff Hamilton, the CEO of Stemson Therapeutics. Stemson Therapeutics is a biotech company founded in 2018 that aims to revolutionize hair regrowth through stem cell technology. So, let’s get into the interview. FT: Hi Geoff, Thank you for coming back to Follicle Thought…
Read MoreNektar Therapeutics Launches a Phase 2b Trial for Alopecia Areata
This week, there is interesting news for those with alopecia areata. Nektar Therapeutics has announced that it will launch a Phase 2b trial for its drug rezpegaldesleukin (REZPEG), which will be assessed in individuals suffering from severe to very severe alopecia areata (AA). Nektar Therapeutics is a biotech firm with several indications in the pipeline…
Read MorePelage Pharma Gains New Injection of Funds to Progress into Phase 2
Pelage Pharma Presents Data From its Phase 1 Clinical Study: Update (03/09/2024) On March 9th, Pelage Pharma unveiled data at the AAD 2024 Annual Meeting, showcasing PP405. Through translational and Phase 1 clinical studies, PP405 demonstrated its ability to reactivate dormant hair follicle stem cells, triggering hair regrowth. Pelage Pharma has provided an overview of…
Read More